Search Result

Results for "

acute-myeloid-leukemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) ADC Cytotoxin (2) AMPK (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (44) Arenavirus (1) Aurora Kinase (2) Autophagy (5) Bacterial (2) Bcl-2 Family (2) Bcr-Abl (4) Biochemical Assay Reagents (2) Btk (2) c-Kit (1) c-Myc (1) Caspase (3) CD3 (1) CDK (6) Checkpoint Kinase (Chk) (1) ClpP (1) CXCR (1) Dihydroorotate Dehydrogenase (6) DNA Alkylator/Crosslinker (2) DNA Methyltransferase (4) DNA/RNA Synthesis (5) Drug Metabolite (2) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (3) Endogenous Metabolite (1) Epigenetic Reader Domain (13) ERK (1) Eukaryotic Initiation Factor (eIF) (1) FLT3 (32) GSK-3 (4) HDAC (10) Histone Demethylase (6) Histone Methyltransferase (2) HIV (1) Integrin (2) Interleukin Related (1) Isocitrate Dehydrogenase (IDH) (4) Isotope-Labeled Compounds (1) JAK (2) KLF (1) Ligands for E3 Ligase (1) MAP4K (1) MDM-2/p53 (3) Mitochondrial Metabolism (2) Mitophagy (1) MNK (1) mTOR (2) NF-κB (1) Oxidative Phosphorylation (3) P-glycoprotein (2) p38 MAPK (1) PDGFR (5) PI3K (2) Pim (2) PROTACs (5) Proteasome (1) RET (2) Ribosomal S6 Kinase (RSK) (1) Salt-inducible Kinase (SIK) (1) STAT (5) Syk (1) TAM Receptor (1) TET Protein (1) Trk Receptor (1) VEGFR (2)
By Research Areas:	Cancer (142) Cardiovascular Disease (1) Infection (4) Inflammation/Immunology (9) Neurological Disease (1)

By Targets:

ADC Antibody (1)

ADC Cytotoxin (2)

AMPK (1)

Antibiotic (1)

Antibody-Drug Conjugates (ADCs) (1)

Apoptosis (44)

Arenavirus (1)

Aurora Kinase (2)

Autophagy (5)

Bacterial (2)

Bcl-2 Family (2)

Bcr-Abl (4)

Biochemical Assay Reagents (2)

Btk (2)

c-Kit (1)

c-Myc (1)

Caspase (3)

CD3 (1)

CDK (6)

Checkpoint Kinase (Chk) (1)

ClpP (1)

CXCR (1)

Dihydroorotate Dehydrogenase (6)

DNA Alkylator/Crosslinker (2)

DNA Methyltransferase (4)

DNA/RNA Synthesis (5)

Drug Metabolite (2)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (3)

Endogenous Metabolite (1)

Epigenetic Reader Domain (13)

ERK (1)

Eukaryotic Initiation Factor (eIF) (1)

FLT3 (32)

GSK-3 (4)

HDAC (10)

Histone Demethylase (6)

Histone Methyltransferase (2)

HIV (1)

Integrin (2)

Interleukin Related (1)

Isocitrate Dehydrogenase (IDH) (4)

Isotope-Labeled Compounds (1)

JAK (2)

KLF (1)

Ligands for E3 Ligase (1)

MAP4K (1)

MDM-2/p53 (3)

Mitochondrial Metabolism (2)

Mitophagy (1)

MNK (1)

mTOR (2)

NF-κB (1)

Oxidative Phosphorylation (3)

P-glycoprotein (2)

p38 MAPK (1)

PDGFR (5)

PI3K (2)

Pim (2)

PROTACs (5)

Proteasome (1)

RET (2)

Ribosomal S6 Kinase (RSK) (1)

Salt-inducible Kinase (SIK) (1)

STAT (5)

Syk (1)

TAM Receptor (1)

TET Protein (1)

Trk Receptor (1)

VEGFR (2)

By Research Areas:

Cancer (142)

Cardiovascular Disease (1)

Infection (4)

Inflammation/Immunology (9)

Neurological Disease (1)

148

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2517

Dihydroevocarpine

mTOR Cancer

Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity .
HY-132969

SBP-3264

Others Cancer

SBP-3264 is a valuable chemical probe for understanding the roles of STK3 and STK4 in acute myeloid leukemia (AML).

Dihydroevocarpine	mTOR	Cancer
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity .

SBP-3264	Others	Cancer
SBP-3264 is a valuable chemical probe for understanding the roles of STK3 and STK4 in acute myeloid leukemia (AML).

HY-15229

Guadecitabine sodium 5+ Cited Publications SGI-110 sodium; S-110 sodium	DNA Methyltransferase	Cancer
Guadecitabine sodium (SGI-110 sodium) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .

HY-139877

OXS007417

Others Cancer

OXS007417 induces differentiation of acute myeloid leukemia cells (EC₅₀ = 48 nM) in vitro and shows antitumor effects in vivo.

OXS007417	Others	Cancer
OXS007417 induces differentiation of acute myeloid leukemia cells (EC₅₀ = 48 nM) in vitro and shows antitumor effects in vivo.

HY-13542

Guadecitabine SGI-110	DNA Methyltransferase	Cancer
Guadecitabine (SGI-110) is a second-generation DNA methyltransferases (DNMT) inhibitor for research of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) .

HY-110071

APcK110

c-Kit Cancer

APcK110 is a potent Kit inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis .

APcK110	c-Kit	Cancer
APcK110 is a potent Kit inhibitor that can be used for the research of acute myeloid leukemia (AML). APcK110 induces AML cell apoptosis .

HY-153714

BN-104 BNM-1192; Menin-MLL inhibitor 27	Epigenetic Reader Domain	Cancer
BN-104 (BNM-1192) can inhibit the Menin-MLL interaction and can be used in cancer research, such as acute myeloid leukemia .

HY-P99971

Gemtuzumab	ADC Antibody	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

HY-160174

BCR-ABL kinase-IN-3

Bcr-Abl Cancer

BCR-ABL kinase-IN-3 (example 1) is a potent inhibitor of BCR-ABL that plays an important role in acute myeloid leukemia (AML) research .

BCR-ABL kinase-IN-3	Bcr-Abl	Cancer
BCR-ABL kinase-IN-3 (example 1) is a potent inhibitor of BCR-ABL that plays an important role in acute myeloid leukemia (AML) research .

HY-135664

hDHODH-IN-5	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-7 is a human dihydroorotate dehydrogenase (DHODH) inhibitor, with an IC₅₀ of 0.91 μM. DHODH-IN-7 induces differentiation in acute myeloid leukemia .

HY-160174A

BCR-ABL kinase-IN-3 (dihydrocholide)	Bcr-Abl	Cancer
BCR-ABL kinase-IN-3 (dihydrocholide) (example 1) is a potent inhibitor of BCR-ABL that plays an important role in acute myeloid leukemia (AML) research .

HY-N0564

Notopterol 1 Publications Verification	Apoptosis	Neurological Disease Inflammation/Immunology Cancer
Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML) .

HY-141680

CPS2 1 Publications Verification	PROTACs CDK	Cancer
CPS2 is a first-in-class, highly potent, selective and irreversible PROTAC CDK2 degrader (IC₅₀= 24 nM). CPS2 can be used for the research of acute myeloid leukemia .

HY-101150

DGN462	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML). DGN462 can be used as a cytotoxic component of antibody-drug conjugates (ADCs) .

HY-101150A

sulfo-DGN462 sodium	DNA Alkylator/Crosslinker ADC Cytotoxin	Cancer
sulfo-DGN462 sodium is degraded to DGN462 in culture medium and plasma. DGN462, a potent DNA-alkylating agent, shows anti-tumor activity, such as acute myeloid leukemia (AML) .

HY-148036

FLT3-IN-16

FLT3 Cancer

FLT3-IN-16 is a potent FLT3 inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

FLT3-IN-16	FLT3	Cancer
FLT3-IN-16 is a potent FLT3 inhibitor with an IC₅₀ of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia .

HY-16271

Kevetrin hydrochloride 4-Isothioureidobutyronitrile hydrochloride; thioureidobutyronitrile hydrochloride; thioureido butyronitrile hydrochloride	MDM-2/p53 Apoptosis	Cancer
Kevetrin hydrochloride is a potent activator of p53, induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells. Kevetrin a preferential cytotoxic activity against blast cells .

HY-162350

TDI-11055	Endogenous Metabolite	Cancer
TDI-11055 is an inhibitor of the epigenetic reader protein 11-19 leukemia (ENL) YEATS, which drives the oncogenic transcriptional program of acute myeloid leukemia (AML), the hematopoietic malignancy AML .

HY-U00442

CTX1 1 Publications Verification	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
CTX1 is a p53 activator that overcomes HdmX-mediated p53 repression. CTX1 exhibits potent anti-cancer activity in a mouse acute myeloid leukemia (AML) model system .

HY-109117

Iadademstat ORY-1001	Histone Demethylase	Cancer
Iadademstat (ORY-1001) is a highly potent, orally active and selective LSD1 (KDM1A) inhibitor with antileukemic activity. Iadademstat can be used for relapsed or refractory acute myeloid leukemia research .

HY-128068

DHODH-IN-17	Dihydroorotate Dehydrogenase	Cancer
DHODH-IN-17, a 2-anilino nicotinic acid, is a human DHODH inhibitor (IC₅₀=0.40 μM). DHODH-IN-17 can be used for theresearch of acute myeloid leukemia (AML) .

HY-157134

Y08262	Others	Cancer
Y08262 is a potent and selective CBP bromodomain inhibitor. Y08262 selectively inhibits the CBP bromodomain with an IC₅₀ value of 73.1 nM. Y08262 can be used for the research of acute myeloid leukemia (AML) .

HY-161149

CM-1758	HDAC	Cancer
CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells .

HY-101025

Nrf2-IN-1 2 Publications Verification
Nrf2-IN-1 is an inhibitor of nuclear factor-erythroid 2-related factor 2 (Nrf2). Nrf2-IN-1 is developed for the research of acute myeloid leukemia (AML) .

HY-148422

Rohinitib	Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
Rohinitib is a potent and specific eIF4A inhibitor. Rohinitib induces cell apoptosis of acute myeloid leukemia (AML) cell lines and reduces the leukemia burden of AML xenograft model. Rohinitib can be used for the research of AML .

HY-163328

DHODH-IN-25	Dihydroorotate Dehydrogenase DNA/RNA Synthesis	Cancer
DHODH-IN-25 (Compound 25) is an orally active dihydroorotate dehydrogenase (DHODH) inhibitor with an IC₅₀ value of 5.4 nM for human DHODH. DHODH-IN-25 can be used for the study of acute myeloid leukemia (AML) .

HY-162088

DW71177	Epigenetic Reader Domain	Inflammation/Immunology
DW71177 is a novel [1,2,4]triazolo[4,3-a] quinoxaline-based potent and BD1-Selective BET inhibitor, and can be used for study of acute myeloid leukemia .

HY-151560

hDHODH-IN-11	Dihydroorotate Dehydrogenase	Cancer
hDHODH-IN-11 is a potent human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC₅₀ value of 7.2 nM. hDHODH-IN-11 has low cytotoxicity. hDHODH-IN-11 can be used in research of acute myeloid leukemia (AML) .

HY-101266

Milademetan 2 Publications Verification DS-3032
Milademetan (DS-3032) is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) induces G1 cell cycle arrest, senescence and apoptosis .

HY-101266B

Milademetan tosylate hydrate 2 Publications Verification DS-3032b; DS-3032 tosylate hydrate	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis .

HY-150586

PTG-0861	HDAC Apoptosis	Cancer
PTG-0861 is a selective histone deacetylase 6 (HDAC6) inhibitor with the IC₅₀ value of 5.92 nM. PTG-0861 induces apoptosis and can be used in the study of acute myeloid leukemia, multiple myeloma and other hematological cancers .

HY-18948

GSK321 1 Publications Verification
GSK321 is a potent inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) enzymes. GSK321 has high inhibitory and selectivity for mutant IDH1 enzymes. GSK321 can be used for the research of acute myeloid leukemia .

HY-16782

Pexmetinib 1 Publications Verification ARRY-614	p38 MAPK Autophagy	Cancer
Pexmetinib is a potent Tie-2 and p38 MAPK dual inhibitor, with IC₅₀s of 1 nM, 35 nM and 26 nM for Tie-2, p38α and p38β, respectively, and can be used in the research of acute myeloid leukemia.

HY-112316

BAY1238097	Epigenetic Reader Domain	Cancer
BAY1238097 is a potent and selective inhibitor of BET binding to histones and has strong anti-proliferative activity in different AML (acute myeloid leukemia) and MM (multiple myeloma) models through down-regulation of c-Myc levels and its downstream transcriptome (IC₅₀ <100 nM).

HY-N0071

Crotonoside Isoguanosine	FLT3 HDAC	Cancer
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-100688

ML390	Dihydroorotate Dehydrogenase	Cancer
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models .

HY-111249

TTT 3002	FLT3	Cancer
TTT 3002 is a potent and orally active FLT3 inhibitor. TTT 3002 potently inhibits FLT3 phosphorylation by activating mutations at residue D835, with an IC₅₀ of 0.2 nM. TTT 3002 can be used for AML (acute myeloid leukemia) research .

HY-124629

DB2313	Apoptosis	Cancer
DB2313 is a potent transcription factor PU.1 inhibitor with an apoptosis of 14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects .

HY-13297

PYZD-4409 1 Publications Verification	E1/E2/E3 Enzyme	Cancer
PYZD-4409 is a specific inhibitor of the ubiquitin-activating enzyme UBA1 with an IC₅₀ of 20 μM (cell-free enzymatic assay). PYZD-4409 induces cell death in malignant cells and preferentially inhibits the clonogenic growth of primary acute myeloid leukemia cells .

HY-13680

Meisoindigo Dian III; N-Methylisoindigotin; Natura-α	Apoptosis	Cancer
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .

HY-139535

Luxeptinib CG-806	FLT3 Btk Apoptosis	Cancer
Luxeptinib (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. Luxeptinib induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells .

HY-134481

FLT3-IN-10	FLT3	Cancer
FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the research of FLT3-mutated acute myeloid leukemia (AML) .

HY-121725

MM-206	STAT	Cancer
MM-206, a STAT3 activity inhibitor, potently inhibits the STAT3 SH2 domain-phosphopeptide interaction with IC₅₀ of 1.2 μM. MM-206 demonstrates dose-dependent induction of apoptosis in acute myeloid leukemia (AML) cell lines .

HY-144782

HDAC10-IN-2	HDAC Autophagy	Cancer
HDAC10-IN-2 (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-144779

HDAC10-IN-1	HDAC Autophagy	Cancer
HDAC10-IN-1 (compound 13b) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 58 nM. HDAC10-IN-1 modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-151634

Syk-IN-6	Syk STAT ERK	Cancer
Syk-IN-6 is an inhibitor of the lipid-SH2 domain interaction, control the cellular activity of kinases containing SH2 domain. Syk-IN-6 blocks Syk kinase activity, which associated hematopoietic malignancies, including acute myeloid leukemia (AML) .

HY-144782A

HDAC10-IN-2 hydrochloride	HDAC Autophagy	Cancer
HDAC10-IN-2 hydrochloride (compound 10c) is a potent and highly selective HDAC10 inhibitor, with an IC₅₀ of 20 nM. HDAC10-IN-2 hydrochloride modulates autophagy in aggressive FLT3-ITD positive acute myeloid leukemia cells .

HY-153939S

Idasanutlin-d3-1 RG7388-d₃-1	Isotope-Labeled Compounds	Cancer
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of MDM2/p53. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia .

HY-P99014

Cusatuzumab 1 Publications Verification	Apoptosis	Inflammation/Immunology
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .

HY-120035

DD1	Proteasome Ribosomal S6 Kinase (RSK) Apoptosis	Cancer
DD1, a proteasome inhibitor, targets Bax activation and P70S6K degradation during acute myeloid leukemia (AML) apoptosis. DD1 induces apoptosis in the caspase-dependent manner. DD1 induces mitochondrial membrane depolarization and Bad dephosphorylation .

Cat. No.	Product Name	Target	Research Area

HY-P99971

Gemtuzumab	ADC Antibody	Cancer
Gemtuzumab is a monoclonal IgG4-κ antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). Gemtuzumab can be used for synthesis of antibody-drug conjugate (ADC), Gemtuzumab ozogamicin (HY-109539). Gemtuzumab ozogamicin consists of a cytotoxic derivative of Calicheamicin (a cytotoxic antibiotic), and a monoclonal antibody. Gemtuzumab ozogamicin can be used for the research of acute myeloid leukemia .

HY-P99014

Cusatuzumab 1 Publications Verification	Apoptosis	Inflammation/Immunology
Cusatuzumab is a human αCD70 monoclonal antibody. Cusatuzumab shows cytotoxicity activity with enhanced antibody-dependent cellular. Cusatuzumab reduces leukemia stem cells (LSCs) and triggers gene signatures related to myeloid differentiation and apoptosis. Cusatuzumab has the potential for the research of Acute myeloid leukemia (AML) .

HY-P99272

Ulocuplumab BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody	CXCR	Cancer
Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .

HY-P99623

Flotetuzumab MGD006; S80880	CD3	Cancer
Flotetuzumab (MGD006; S80880) is an investigational CD123/CD3 bispecific dual-affinity retargeting antibody (DART) molecule. Flotetuzumab reactivates T cells by simultaneously binding to CD123 in target cells and CD3 in effector T cells, leading to T-cell-mediated cytotoxicity in target cells. Flotetuzumab shows inhibitory effect on a mouse model of patient-derived xenograft (PDX) in acute myeloid leukemia (AML) .

HY-P99958

Vixtimotamab AMV-564; TandAb T564	Inhibitory Antibodies	Cancer
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML) .

HY-P99395

Talacotuzumab JNJ 56022473; CSL 362	Interleukin Related	Cancer
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has K_Ds of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2517

Dihydroevocarpine	Alkaloids Classification of Application Fields Source classification Evodia rutaecarpa (Juss.) Benth. Rutaceae Quinoline Alkaloids Plants Disease Research Fields Cancer	mTOR
Dihydroevocarpine induces cytotoxicity in acute myeloid leukemia via suppressing the mTORC1/2 activity .

HY-N0564

Notopterol 1 Publications Verification	Classification of Application Fields Neurological Disease Isodon excisoides (Sun ex C. H. Hu) H. Hara Source classification Coumarins Phenylpropanoids Plants Umbelliferae Disease Research Fields Inflammation/Immunology	Apoptosis
Notopterol is a coumarin extracted from N. incisum. Notopterol induces apoptosis and has antipyretic, analgesic and anti-inflammatory effects. Notopterol is used for acute myeloid leukemia (AML) .

HY-N0071

Crotonoside Isoguanosine	Alkaloids Structural Classification Classification of Application Fields Croton tiglium Linn. Source classification Euphorbiaceae Plants Disease Research Fields Cancer	FLT3 HDAC
Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML .

HY-13680

Meisoindigo Dian III; N-Methylisoindigotin; Natura-α	Alkaloids Structural Classification other families Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Cancer	Apoptosis
Meisoindigo (Dian III), a derivative of Indirubin (HY-N0117), halts the cell cycle at the G0/G1 phase and induces apoptosis in primary acute myeloid leukemia (AML) cells. Meisoindigo exhibits high antitumor activity .

HY-N2492

(E)-Methyl 4-coumarate Methyl trans-p-coumarate	Infection Monophenols Classification of Application Fields Source classification Rubiaceae Morinda citrifolia Linn. Other Phenylpropanoids Phenols Phenylpropanoids Plants Disease Research Fields	Bacterial Apoptosis
(E)-Methyl 4-coumarate (Methyl 4-hydroxycinnamate), found in several plants, such as Allium cepa or Morinda citrifolia L. leaves. (E)-Methyl 4-coumarate cooperates with Carnosic Acid in inducing apoptosis and killing acute myeloid leukemia cells, but not normal peripheral blood mononuclear cells. Antioxidant and antimicrobial activity.

HY-123121

Nargenicin A1	Infection Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Inflammation/Immunology Disease Research Fields Cancer	Antibiotic Apoptosis Bacterial NF-κB
Nargenicin A1 is an antibiotic agent against various Gram-positive bacteria. Nargenicin A1 shows anti-inflammatory activity. Nargenicin A1 protects HINAE cells against Tacrolimus (HY-13756)-induced DNA damage and apoptosis. Nargenicin A1 can also be used for the research of acute myeloid leukemia .

Cat. No.	Product Name	Chemical Structure

HY-153939S

Idasanutlin-d3-1
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of MDM2/p53. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia .

HY-50907S

ABT-737-d8

ABT 737-d₈ is the deuterium labeled ABT-737. ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks